ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)

Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome. Vice versa, targeted inhibition of BRAF-V600E with the selective inhibitor PLX 4032 (Vemurafenib) is severely limited due to f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Prasetyanti, Pramudita R., Capone, Emily, Barcaroli, Daniela, D'Agostino, Daniela, Volpe, Silvia, Benfante, Antonina, van Hooff, Sander, Iacobelli, Valentina, Rossi, Cosmo, Iacobelli, Stefano, Medema, Jan Paul, De Laurenzi, Vincenzo, Sala, Gianluca
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Priority Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627280/
https://ncbi.nlm.nih.gov/pubmed/26160848
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars